Duvelisib not checked
SecuraBio · IPI-145 · PI3K Inhibitor
FollowEvery change as it happens, and a Monday email
Trials
2 active
24 in total · 1 in the EU
What this is
- How it works
- Blocks PI3K, an enzyme that passes growth signals inside cells. Mostly used against cancer.-lisib: PI3K inhibitors WHO name stem
- Tested for
- Lymphoma, Mycosis Fungoides, Cutaneous T-cell Lymphoma
- Main trialPhase 3
- “The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.”In the company’s words, NCT06522737 on ClinicalTrials.gov
- Other names
- IPI-145 · Copiktra · PI3K Inhibitor · SBI-0145 · VS-0145
Other drugs for Lymphoma
- GlofitamabRoche · Phase 3
- ObinutuzumabRoche · Phase 3
- TocilizumabRoche · Phase 3
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
- XNW5004Evopoint Biosciences Inc. · Phase 3
Coming up2
- Feb 2028Phase 3 trial completes · ClinicalTrials.gov
- Oct 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials24
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Feb 2028 | A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype | |
| Phase 1Not yet recruiting | Oct 2028 | A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides | |
| Phase 3Withdrawn | Nov 2016 | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | |
| Phase 3Terminated | Dec 2016 | Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma | |
| Phase 3Completed | 19 May 2017 | A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) | |
| Phase 3Completed | 12 Jun 2020 | A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 | |
| Phase 2Completed | Aug 2014 | A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects | |
| Phase 2Completed | Dec 2014 | A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone | |
| Phase 2Withdrawn | Nov 2016 | Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) | |
| Phase 2Completed | 4 May 2020 | A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145) | |
| Phase 2Withdrawn | Jun 2020 | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | |
| Phase 2Completed | 18 Nov 2020 | A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma | |
| Phase 2Completed | 24 Jul 2023 | A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma | |
| Phase 2Completed | 22 Dec 2023 | A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | |
| Phase 1/2Terminated | 17 Jan 2017 | A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) | |
| Phase 1/2Terminated | 10 Dec 2020 | A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | |
| Phase 1Completed | Feb 2012 | IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study | |
| Phase 1Completed | Apr 2013 | IPI-145 ADME and Absolute Bioavailability Study | |
| Phase 1Completed | Sep 2013 | Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam | |
| Phase 1Completed | Nov 2013 | Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145 | |
| Phase 1Completed | Jul 2014 | Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects | |
| Phase 1Completed | Aug 2015 | Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145 | |
| Phase 1Terminated | Nov 2016 | Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) | |
| Phase 1Terminated | Dec 2016 | A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026